12 March 2008
The London Stock Exchange is delighted to welcome BHK Inc. to AIM.
BHK is a Korean developer and manufacturer of medical and digital technology. The company operates cell therapy and artificial organs businesses focused on developing products for the treatment of major organ failure, particularly heart failure.
The Company is listed on the Korea Exchange and is introducing two million GDRs to AIM.
Alex Choi, Chairman and CEO of BHK, said:
“It is a pleasure to announce BHK’s successful admission to AIM. This is an important part of our growth strategy, as an additional listing in London will enhance our reputation in key markets and provide greater access to new capital.
BHK possesses a different business model to traditional biotech companies by combining its two medical arms with the benefits of a cash generative digital division, which provides both revenue and complementary technologies. We look forward to generating continued value for our existing shareholders as well as attracting new investors.”
Deloitte Corporate Finance is acting as BHK’s Nominated Adviser and Lewis Charles Securities as its Broker. Deloitte &Touche LLP is acting as reporting accountants and Cardew Group as Financial PR advisers.